News
IMUX
6.99
-5.41%
-0.40
Analysts Are Bullish on These Healthcare Stocks: MetaVia (MTVA), Immunic (IMUX)
TipRanks · 2d ago
Immunic: Buy Rating and $22 Price Target Maintained Ahead of ENSURE Phase 3 MS Results
TipRanks · 4d ago
Weekly Report: what happened at IMUX last week (1109-1113)?
Weekly Report · 4d ago
Morning Movers: Microsoft lower amid continued outage of 365 services
TipRanks · 11/13 13:55
Immunic Q3 Loss Widens On Higher Expenses; Phase 3 MS Trial Data Expected In December 2026
NASDAQ · 11/13 11:59
Immunic reports Q3 EPS (99c), consensus (95c)
TipRanks · 11/13 11:35
Immunic Q3 EPS $(0.99) Misses $(0.96) Estimate
Benzinga · 11/13 11:34
Immunic GAAP EPS of -$0.99 misses by $0.04
Seeking Alpha · 11/13 11:32
Press Release: Immunic, Inc. Reports Third -2-
Dow Jones · 11/13 11:30
Press Release: Immunic, Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Dow Jones · 11/13 11:30
Press Release: Immunic, Inc. Reports Third -3-
Dow Jones · 11/13 11:30
*Immunic 3Q Loss $42.3M >IMUX
Dow Jones · 11/13 11:30
*Immunic 3Q Loss/Shr 99c >IMUX
Dow Jones · 11/13 11:30
Immunic: Q3 Earnings Snapshot
Barchart · 11/13 05:36
Guggenheim Remains a Buy on Immunic (IMUX)
TipRanks · 11/09 13:56
Analysts Offer Insights on Healthcare Companies: Disc Medicine (IRON) and Immunic (IMUX)
TipRanks · 11/09 10:40
Weekly Report: what happened at IMUX last week (1102-1106)?
Weekly Report · 11/09 10:03
Analyst Maintains Buy Rating and Unchanged $22 Price Target on Immunic, Citing Vidofludimus Potential in Progressive MS
TipRanks · 11/06 13:59
Immunic, Inc. Hosts Progressive Multiple Sclerosis Research and Development Day Webinar on November 5, 2026
NASDAQ · 11/06 04:48
Immunic Hosts Progressive Multiple Sclerosis R&D Day Webinar
TipRanks · 11/05 14:32
More
Webull provides a variety of real-time IMUX stock news. You can receive the latest news about Immunic Inc through multiple platforms. This information may help you make smarter investment decisions.
About IMUX
Immunic, Inc. is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is engaged in pursuing clinical development of programs, which include the vidofludimus calcium (IMU-838) program, which is in Phase III clinical development for patients with relapsing multiple sclerosis (RMS), and which has shown therapeutic activity in Phase II clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis; the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, Graft-versus-Host-Disease and weight management, and the IMU-381 program, which is a molecule being developed to specifically address the needs of gastrointestinal diseases.